DARA BioSciences Announces Participation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City

DARA BioSciences Announces Participation at the 15th Annual Rodman & Renshaw 
Global Investment Conference in New York City September 8-10,
2013 
Live Webcast of DARA's Presentation on Tuesday, September 10 at 10:30
a.m. ET 
RALEIGH, NC  -- (Marketwired) -- 09/05/13 --   DARA BioSciences, Inc.
(NASDAQ: DARA), a specialty pharmaceutical company focused on the
commercialization of its complementary product portfolio of oncology
and oncology supportive care products, announced today that it will
be featured as a presenting company at the 15th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held September 8-10, 2013, at the
Millennium Broadway Hotel in New York City.  
David J. Drutz, MD, DARA BioSciences' CEO and CMO will provide an
overview of the Company's business during the live presentation on
Tuesday, September 10, 2013 at 10:00 a.m. ET and will be available to
participate in one-on-one meetings with investors who are registered
to attend the conference.  
Dr. Drutz' presentation will be webcast live. To access the webcast,
please visit www.rodm.com. The webcast replay will remain available
for 90 days following the live presentation.  
About Rodman & Renshaw Conferences, LLC
The Rodman & Renshaw Annual Global Investment Conference is an
informational service and networking opportunity for companies and
investors. Rodman does not prepare, review or edit the presentations
and other information provided by each company, and does not take any
responsibility for the accuracy or adequacy of any such information
as the basis for any investment decision. Rodman is not providing any
person with any investment advice through their participation in or
attendance of the Conference, nor is Rodman soliciting any offers to
buy or sell any security of any company. 
About DARA BioSciences, Inc. 
DARA is a specialty pharmaceutical company focused on the
commercialization of its complementary product portfolio of oncology
and oncology supportive care products.  
DARA increased its focus in oncology through its January 2012
acquisition of Oncogenerix, Inc., which holds the exclusive U.S.
marketing rights to Soltamox®, a novel oral liquid formulation of
tamoxifen citrate, which is wid
ely used in the treatment and
prevention of breast cancer. Soltamox is the only FDA-approved oral
liquid version of tamoxifen citrate and fulfills an important
clinical need for patients who prefer a liquid formulation or cannot
tolerate existing solid tablet formulations of this drug. DARA has
exclusive U.S. rights to Soltamox through a license from Rosemont
Pharmaceuticals, Ltd.  
In June 2012, DARA launched its first product, Bionect®, a topical
treatment for skin irritation and burns associated with radiation
therapy. DARA has rights to market Bionect in the US
oncology/radiology markets under license from Innocutis. Soltamox was
launched formally as DARA's second commercial product in December
2012, coincident in timing with the 35th Annual San Antonio Breast
Cancer Symposium. In late April, 2013, DARA launched its third
product, Gelclair®, an FDA-cleared product for the treatment of oral
mucositis for which DARA also has exclusive U.S. commercial rights
through a license from Helsinn Group in Switzerland.  
DARA also has a clinical development asset, KRN5500, which is a Phase
2 product candidate targeted for treating cancer patients with
painful treatment-refractory chronic chemotherapy-induced peripheral
neuropathy (CCIPN) in patients with cancer. This product is an
excellent fit with DARA's strategic oncology focus, has successfully
completed a Phase 2a clinical trial, and has been designated a Fast
Track Drug by the FDA. DARA has created an improved, potentially
commercializable formulation of this drug and is in active partnering
discussions regarding further clinical development. DARA has also
submitted an Orphan Drug Application to the FDA for the use of this
drug in painful treatment-refractory CCIPN.  
For more information please visit our web site at www.darabio.com.  
Safe Harbor Statement
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Important factors that
could cause actual results to differ materially from the expectations
described in these forward-looking statements include risks and
uncertainties relating to DARA's ability to timely commercialize and
generate revenues or profits from Bionect®, Soltamox®, Gelclair® or
other products and DARA's lack of history as a revenue-generating
company, FDA and other regulatory risks relating to DARA's ability to
market Bionect, Soltamox, Gelclair or other products in the U.S. or
elsewhere, DARA's current cash position and its need to raise
additional capital in order to be able to continue to fund its
operations, the current regulatory environment in which DARA sells
its products, the market acceptance of those products, dependence on
partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors identified
in DARA's Annual Report on Form 10-K filed the SEC on March 28, 2013
and in DARA's periodic filings with the SEC. Copies of DARA's filings
with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov. DARA expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DARA's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.
DARA BioSciences and the DARA logo are trademarks of DARA
BioSciences, Inc. 
Investor contact:                                           
Jenene Thomas                                            
DARA BioSciences                                       
908-938-1475                                               
jthomas@darabio.com 
Media contact:
David Connolly or Samantha Stenbeck
LaVoie Group
617-374-8800
dconnolly@lavoiegroup.com
sstenbeck@lavoiegroup.com